Symptoms and General Pathology

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Heart and Blood Diseases

Rare Diseases

Sclerosis

Neoplasm Metastasis

Scleroderma, Systemic

Scleroderma, Diffuse

Raynaud Disease

Neoplastic Processes

Connective Tissue Diseases

Skin Diseases

Vascular Diseases

Livedoid Vasculopathy

Thrombosis

Embolism

Embolism and Thrombosis

Peripheral Arterial Disease

Peripheral Vascular Diseases

Skin Diseases, Vascular

Systemic Scleroderma

Antihypertensive Agents

All Drugs and Chemicals

Selexipag

Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.

Placebo matching selexipag tablets is administered according to the same schedule as selexipag

Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily

Placebo matching selexipag 200 μg tablets to be administered orally twice daily

Placebo

Ralph Preiss, MD

The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

QOL is assessed by the Scleroderma Health Assessment Questionnaire (SHAQ)

The number of RP attacks is determined from daily entries in electronic Diaries (eDiary).

A treatment-emergent adverse event is any adverse event (AE) temporally associated with the use of a study treatment, whether or not considered related to the study treatment, including any abnormalities in ECG parameters, vital signs or laboratory tests

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis	NCT02260557	Raynaud's Pheno...	Selexipag Placebo	18 Years -	Actelion
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis	NCT02260557	Raynaud's Pheno...	Selexipag Placebo	18 Years -	Actelion

Spots Global Cancer Trial Database for selexipag

Every month we try and update this database with for selexipag cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for selexipag

Every month we try and update this database with for selexipag cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for selexipag cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.